No, the PR is dated TODAY about the expanded 60 patient data study. The initial 40 patient study data was presented a year ago.
GAITHERSBURG, Maryland, June 27, 2017 /PRNewswire/ --
- Theralink predicts 5-year survival for patients in response to standard of care
- Negative predictive value allows physicians to change treatment decisions
Avant Diagnostics, Inc. ('Avant') (OTC: AVDX), an oncology-focused healthcare technology company commercializing the proprietary Theralink® proteomic biomarker platform announced positive clinical utility data, the confirmation of the clinical utility of the Theralink® Pancreatic Cancer assay in an expanded 60 patient data study in distinguishing patients that will experience a 5-year survival outcome following standard of care treatment regimens, versus those likely to experience significantly worse outcomes. The initial 40 patient study set was presented at The International Symposium on Pancreas Cancer 2016. The Company is evaluating the commercial potential of this assay to assist physicians in making prescribing decisions, as well as helping pharmaceutical companies and research institutions to develop novel treatment paradigms for pancreatic cancer.
"The ability to accurately predict which patients will respond to standard of care treatment, and equally importantly those who will not respond may have a significant impact on oncologists' prescribing habits in the challenging area of pancreatic cancer treatment," said Vincent J. Picozzi, Jr., MD, Director of the pancreaticobiliary program at the Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center. He further added, "There is tremendous value in identifying patients less likely to respond to treatment early on, so that oncologists can move more rapidly to different treatment regimens that may have the potential to benefit patients earlier on in disease progression. I look forward to working with the team at Avant to publish the data, and help them develop strategies to bring this incredibly important technology towards the marketplace."
